Collaborating Authors


FDA Clears World's First AI-Driven Portable 3D Breast Ultrasound Scanner


This week iSono Health announced FDA clearance of the company's ATUSA System for breast imaging. This is world's first AI-driven portable and automated 3D breast ultrasound scanner. In just 2 minutes, the ATUSA system automatically scans the entire breast volume, independent of operator expertise, and offers 3D visualization of the breast tissue. The ATUSA system is designed from the ground up to seamlessly integrate with advanced machine learning models that will give physicians a comprehensive set of tools for decision making and patient management. This is the first of several intended FDA submissions for the company.

How A.I. Is Finding New Cures in Old Drugs


In the elegant quiet of the café at the Church of Sweden, a narrow Gothic-style building in Midtown Manhattan, Daniel Cohen is taking a break from explaining genetics. He moves toward the creaky piano positioned near the front door, sits down, and plays a flowing, flawless rendition of "Over the Rainbow." If human biology is the scientific equivalent of a complicated score, Cohen has learned how to navigate it like a virtuoso. Cohen was the driving force behind Généthon, the French laboratory that in December 1993 produced the first-ever "map" of the human genome. He essentially introduced Big Data and automation to the study of genomics, as he and his team demonstrated for the first time that it was possible to use super-fast computing to speed up the processing of DNA samples.

AI, ML, & Cybersecurity: Here's What FDA May Soon Be Asking


FDA has released a number of documents that could help clarify its expectations for artificial intelligence, machine learning, and cybersecurity. These include Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan, published in January 2021; Good Machine Learning Practice for Medical Device Development: Guiding Principles, published in October 2021; and the just-released draft guidance, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. The AI/ML action plan provides a "more tailored regulatory framework for AI/ML," explained Pavlovic. She referred to FDA's 2019 discussion paper, Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) - Discussion Paper and Request for Feedback, which laid out a "total product lifecycle approach to AI/ML regulations with the understanding that AI/ML products can be iterated much more efficiently and quickly than a typical medical device implant product or something that isn't software based." This is "because there is an opportunity to add additional data to training sets on which the products were originally formulated," she said.

Artificial Intelligence for Synthetic Biology

Communications of the ACM

AI techniques have been leveraged that combine known biophysical, machine learning, and reinforcement learning models to effectively predict the constructs' impact on the host and vice versa, but there is much room for improvement.

Artificial Intelligence Market Size to Surpass Around US$ 1,597.1 Bn By 2030


Ottawa, April 19, 2022 (GLOBE NEWSWIRE) -- The global artificial intelligence (AI) market size was valued at US$ 87.04 billion in 2021. The artificial intelligence technology has gained a rapid traction since its introduction in the market. The rising demand for artificial intelligence technology across various induce verticals such as a retail, BFSI, healthcare, food and beverages, automotive, and logistics is significantly contributing towards the growth of the global artificial intelligence market. Furthermore, the rising adoption of the AI technology in the pharmaceutical manufacturing is expected to have a significant impact on the market growth in the forthcoming years. The biopharmaceutical companies are increasingly adopting the artificial intelligence technology in various applications such as research, drug discovery, and clinical trials, which is significantly fueling the demand for artificial intelligence technology across the globe. The growing penetration of advanced digital technologies across the globe in various application is supporting the growth of the AI market.

The Strategy That Will Fix Health Care


In health care, the days of business as usual are over. Around the world, every health care system is struggling with rising costs and uneven quality despite the hard work of well-intentioned, well-trained clinicians. Health care leaders and policy makers have tried countless incremental fixes--attacking fraud, reducing errors, enforcing practice guidelines, making patients better "consumers," implementing electronic medical records--but none have had much impact. At its core is maximizing value for patients: that is, achieving the best outcomes at the lowest cost. We must move away from a supply-driven health care system organized around what physicians do and toward a patient-centered system organized around what patients need. We must shift the focus from the volume and profitability of services provided--physician visits, hospitalizations, procedures, and tests--to the patient outcomes achieved. And we must replace today's fragmented system, in which every local provider offers a full range of services, with a system in which services for particular medical conditions are concentrated in health-delivery organizations and in the right locations to deliver high-value care. Making this transformation is not a single step but an overarching strategy. We call it the "value agenda." It will require restructuring how health care delivery is organized, measured, and reimbursed. In 2006, Michael Porter and Elizabeth Teisberg introduced the value agenda in their book Redefining Health Care. Since then, through our research and the work of thousands of health care leaders and academic researchers around the world, the tools to implement the agenda have been developed, and their deployment by providers and other organizations is rapidly spreading. The transformation to value-based health care is well under way. Some organizations are still at the stage of pilots and initiatives in individual practice areas. Other organizations, such as the Cleveland Clinic and Germany's Schön Klinik, have undertaken large-scale changes involving multiple components of the value agenda. The result has been striking improvements in outcomes and efficiency, and growth in market share. There is no longer any doubt about how to increase the value of care. The question is, which organizations will lead the way and how quickly can others follow? The challenge of becoming a value-based organization should not be underestimated, given the entrenched interests and practices of many decades. This transformation must come from within.

The Global Takeover Hinges on Pandemics and Transhumanism - Verve times


Have you ever watched any of the "Terminator" movies with Arnold Schwarzenegger? If you have, you will be familiar with the evil villain "Skynet," which is a fictional artificial, neural network-based, conscious group-mind and artificial general superintelligence system that decided to terminate all human life in the late 2020s. It has become palpably obvious that the company that most closely resembles Skynet today is Google. You may recall that Google purchased the leading artificial intelligence company Deep Mind a little over eight years ago for the paltry sum of $500 million. This was likely the most important purchase Google made to jumpstart them to Skynet status, with their already massive surveillance capacity corralling data collected from its search engine, which controls 93% of the searches in the world.

Aidoc Gets FDA 510(k) Clearance for AI-Powered Algorithm for Brain Aneurysms


Could a new artificial intelligence (AI)-enabled advance have an impact in the diagnosis and treatment of brain aneurysms? The Food and Drug Administration (FDA) has granted 510(k) clearance to Aidoc's new AI platform for brain aneurysms. In addition to identifying and triaging suspected cases, the algorithm facilitates communication and workflow between radiologists, neurologists and neuroendovascular surgeons, according to the company. Researchers have estimated that approximately 6.5 million people in the United States have an unruptured brain aneurysm.1 The Brain Aneurysm Foundation has noted that most aneurysms are small, ranging from 1/8 inch to an inch, and ruptured aneurysms are reportedly misdiagnosed or there is a delay in diagnosis in 25 percent of patients who present to health-care providers.1 Elad Walach, the CEO and co-founder of Aidoc, said the new AI-enabled algorithm may help enhance timely diagnosis and care for brain aneurysms.

Four trends showcase artificial intelligence in healthcare


There is a common misconception that once AI becomes embedded in healthcare processes, it will take away human jobs. That scenario is unlikely to occur, however, because AI's true role is to aggregate and analyze reams of data. That task is difficult for humans, so AI will be a welcome partner in clinical decision-making. This stance is supported by Scott Gottlieb, former commissioner at the Food and Drug Administration (FDA) and now a board member at Pfizer and Illumina. He is also a senior fellow at the American Enterprise Institute, a public policy firm.

Can You Code Empathy? with Pascale Fung


ANJA KASPERSEN: Today I am very pleased to be joined by Pascale Fung. Pascale is a;rofessor in the Department of Electronic and Computer Engineering and Department of Computer Science and Engineering at The Hong Kong University of Science and Technology. She is known globally for her pioneering work on conversational artificial intelligence (AI), computational linguistics, and was one of the earliest proponents of statistical and machine-learning approaches for natural language processing (NLP). She is now leading groundbreaking research on how to build intelligent systems that can understand and empathize with humans. I have really been looking forward to this conversation with you. Your professional accolades are many, most of which we will touch on during our conversation. However, for our listeners to get to know you a bit better, I would like us to go back to your upbringing during what I understand to be a very tenuous political period in China. I was born, spent my childhood, ...